Manmeet Singh Soni
Net Worth

Last updated:

What is Manmeet Singh Soni net worth?

The estimated net worth of Mr. Manmeet Singh Soni is at least $27,214,299 as of 16 Aug 2023. He has earned $21,564,299 from insider trading and has received compensation worth at least $5,650,000 in Reata Pharmaceuticals, Inc..

What is the salary of Manmeet Singh Soni?

Mr. Manmeet Singh Soni salary is $1,130,000 per year as Chief Operating Officer, Chief Financial Officer & Executive Vice President in Reata Pharmaceuticals, Inc..

How old is Manmeet Singh Soni?

Mr. Manmeet Singh Soni is 47 years old, born in 1978.

What stocks does Manmeet Singh Soni currently own?

As insider, Mr. Manmeet Singh Soni owns shares in one company:

Company Title Shares Price per share Total value
Reata Pharmaceuticals, Inc. (RETA) Chief Operating Officer, Chief Financial Officer & Executive Vice President 62,621 $0 $0

What does Reata Pharmaceuticals, Inc. do?

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Manmeet Singh Soni insider trading

Reata Pharmaceuticals, Inc.

Mr. Manmeet Singh Soni has made 13 insider trades between 2020-2023, according to the Form 4 filled with the SEC. Most recently he sold 1,755 units of RETA stock worth $295,567 on 16 Aug 2023.

The largest trade he's ever made was exercising 75,000 units of RETA stock on 28 Jul 2023. As of 16 Aug 2023 he still owns at least 62,621 units of RETA stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Class A common stock 1,755 $168.41 $295,567
Option
Class B common stock 75,000 N/A N/A
Option
Employee Stock Option (right to buy) 75,000 $72.7 $5,452,500
Sale
Class A common stock 75,000 $164.62 $12,346,275
Sale
Class A common stock 16,163 $101.99 $1,648,384
Sale
Class A common stock 9,157 $101.05 $925,351
Sale
Class A common stock 250 $105.55 $26,388
Sale
Class A common stock 14,016 $105.05 $1,472,367
Option
Employee Stock Option (right to buy) 25,000 $27.32 $683,000
Sale
Class A common stock 9,326 $99.75 $930,241
Sale
Class A common stock 25,530 $104.09 $2,657,392
Option
Class A common stock 25,000 $27.32 $683,000
Sale
Class A common stock 3,643 $102.73 $374,227
Sale
Class A common stock 4,711 $99.62 $469,296
Sale
Class A common stock 625 $80.93 $50,584
Sale
Class A common stock 622 $84.7 $52,680
Sale
Class A common stock 3,587 $87.97 $315,548
Purchase
Class A common stock 16,000 $26.22 $419,568
Purchase
Class A common stock 3,000 $50.11 $150,330

Reata Pharmaceuticals key executives

Reata Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: